Sai Life Sciences Unveils New CMC Process R&D Center in Hyderabad

Sai Life Sciences Limited, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) in India, has revealed plans for a new CMC Process R&D Center at its Hyderabad campus, scheduled for completion by September 2026. The project aims to double the company's process R&D capacity, incorporating advanced capabilities in peptide, oligo intermediates, formulation development, and clinical supplies.

CEO and Managing Director Krishna Kanumuri noted that the center aligns with the demand for rapid, flexible drug development solutions, enhancing the company's ability to integrate scientific excellence with operational agility. Key features of the facility include a 100,000 sq. ft. space over five floors, 140 process chemistry fume hoods, and specialized labs for peptides and oligo intermediates.

This strategic investment underscores Sai Life Sciences' commitment to sustainability and specialization, providing flexible collaboration opportunities with global drug innovators. It is part of the company's capital expenditure strategy, responding to the rising demand for clinical-scale programs and late-stage pipeline developments.